Your browser doesn't support javascript.
loading
From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation.
Wang, Siqi; He, Fuchu; Tian, Chunyan; Sun, Aihua.
Affiliation
  • Wang S; State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing 102206, China.
  • He F; State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing 102206, China.
  • Tian C; Research Unit of Proteomics Dirven Cancer Precision Medicine, Chinese Academy of Medical Sciences, Beijing 100050, China.
  • Sun A; State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing 102206, China.
Pharmaceuticals (Basel) ; 17(1)2024 Jan 11.
Article in En | MEDLINE | ID: mdl-38256933
ABSTRACT
PROTAC is a rapidly developing engineering technology for targeted protein degradation using the ubiquitin-proteasome system, which has promising applications for inflammatory diseases, neurodegenerative diseases, and malignant tumors. This paper gives a brief overview of the development and design principles of PROTAC, with a special focus on PROTAC-based explorations in recent years aimed at achieving controlled protein degradation and improving the bioavailability of PROTAC, as well as TPD technologies that use other pathways such as autophagy and lysosomes to achieve targeted protein degradation.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Pharmaceuticals (Basel) Year: 2024 Document type: Article Affiliation country: China Country of publication: Suiza

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Pharmaceuticals (Basel) Year: 2024 Document type: Article Affiliation country: China Country of publication: Suiza